Tag: Pulmonary Hypertension

Bellerophon Updates Ongoing Phase 2b Trial

Bellerophon Therapeutics announced the completion of enrolment for its iNO-PF trial and said it expects top-line results in January 2019.

Bellerophon Provides Update on INOpulse Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled...